Literature DB >> 31569063

Transcriptomics-based screening of molecular signatures associated with patients overall survival and their key regulators in subtypes of breast cancer.

Elaheh Eskandari1, Jamshid Motalebzadeh2.   

Abstract

Molecular subtypes of breast cancer are associated with differences in prognosis and strategies of molecular targeted therapies. Gene regulatory mechanisms as one of the reasons might modulate these differences. In the present study, we proposed a comprehensive data analysis and systems biology approach to explore molecular signatures which reduce the chance of patients overall survival and the possible mechanisms of their regulation by transcription factors (TFs) and microRNAs (miRNAs) in the main subtypes of breast tumor consist of Basal like, Her2 enriched, Luminal A and Luminal B breast cancer. In this regards, we used available microarray datasets to assess common differentially expressed genes (DEGs) in breast cancer subtypes. Using Kaplan-Meier curve analysis we identified common DEGs which are associated with decreasing in the overall survival of breast cancer patients. Furthermore, gene regulatory networks (GRNs) were depicted based on TFs and miRNAs with interest target genes. Then GRNs were analyzed and using five algorithms (Control centrality, Betweenness, Degree, Classification, and MCDS) the key regulators were identified for each subtype. In this study, we highlighted mechanisms underlying the regulation of breast cancer molecular signatures by TFs and miRNAs which their alteration reduce the chance of survival rate in each subtype of breast cancer. Our current study in a holistic insight revealed the importance of some genes and their regulators as potential prognostic markers and/or therapeutic targets in breast cancer patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer subtypes; Gene regulatory network; Micro-RNAs; Molecular signature; Prognosis; Transcription factors

Mesh:

Substances:

Year:  2019        PMID: 31569063     DOI: 10.1016/j.cancergen.2019.09.004

Source DB:  PubMed          Journal:  Cancer Genet


  7 in total

1.  Transcription factors linked to the molecular signatures in the development of hepatocellular carcinoma on a cirrhotic background.

Authors:  Jamshid Motalebzadeh; Elaheh Eskandari
Journal:  Med Oncol       Date:  2021-09-01       Impact factor: 3.064

2.  Comprehensive analysis of DRAIC and TP53TG1 in breast cancer luminal subtypes through the construction of lncRNAs regulatory model.

Authors:  Jamshid Motalebzadeh; Elaheh Eskandari
Journal:  Breast Cancer       Date:  2022-07-24       Impact factor: 3.307

3.  Hypermethylated KLF9 Is An Independent Prognostic Factor For Favorable Outcome In Breast Cancer.

Authors:  Lei Wang; Qiqi Mao; Shaocheng Zhou; Xiaochun Ji
Journal:  Onco Targets Ther       Date:  2019-11-18       Impact factor: 4.147

4.  Identification and Potential Mechanisms of a 7-MicroRNA Signature That Predicts Prognosis in Patients with Lower-Grade Glioma.

Authors:  Zhizheng Liu; Hongliang Meng; Miaoxian Fang; Wenlong Guo
Journal:  J Healthc Eng       Date:  2021-11-20       Impact factor: 2.682

5.  Analysis of Breast Cancer Based on the Dysregulated Network.

Authors:  Yanhao Huo; Xianbin Li; Peng Xu; Zhenshen Bao; Wenbin Liu
Journal:  Front Genet       Date:  2022-02-15       Impact factor: 4.599

6.  A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.

Authors:  Jian-Hua Zhang; Ruiqin Hou; Yuhualei Pan; Yuhan Gao; Ying Yang; Wenqin Tian; Yan-Bing Zhu
Journal:  J Cell Mol Med       Date:  2020-05-15       Impact factor: 5.310

Review 7.  Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype.

Authors:  Andrea Angius; Paolo Cossu-Rocca; Caterina Arru; Maria Rosaria Muroni; Vincenzo Rallo; Ciriaco Carru; Paolo Uva; Giovanna Pira; Sandra Orrù; Maria Rosaria De Miglio
Journal:  Cancers (Basel)       Date:  2020-11-07       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.